Introduction {#ics12540-sec-0005}
============

Exposure of human skin to ultraviolet radiation (UVR) leads to a myriad of acute and chronic effects. The most prominent acute effects include erythema, pigmentation and immunosuppression, while the most prominent chronic effects comprise photocarcinogenesis and photoageing. All these effects are caused by alterations on a molecular or cellular level, including DNA damage, formation of reactive oxygen species (ROS) and inflammatory mediators, melanogenesis and apoptosis [1](#ics12540-bib-0001){ref-type="ref"}, [2](#ics12540-bib-0002){ref-type="ref"}, [3](#ics12540-bib-0003){ref-type="ref"}.

With continued year‐on‐year increases in skin cancer rates [4](#ics12540-bib-0004){ref-type="ref"}, dermatologists strongly recommend the use of sunscreens to help protect against solar UVR [5](#ics12540-bib-0005){ref-type="ref"}.

The level of protection against erythema ("sunburn") provided by sunscreen products is expressed as the Sun Protection Factor (SPF). The derived SPF value represents the ratio of the dose of solar‐simulated UVR required to induce erythema with and without sunscreen (applied *in vivo* to the skin of human volunteers [2](#ics12540-bib-0002){ref-type="ref"}. In Europe, Canada, Australia and Japan, SPF is determined using the *in vivo* International Standard method ISO24444:2010 [6](#ics12540-bib-0006){ref-type="ref"}.

By definition, sunscreens can never be 100% effective in preventing solar UVR transmission. Even with an SPF50 product, 2% of incident erythemally‐effective solar UVR is still transmitted through the product layer, into the skin. Following UVR exposure, acute activation of inflammatory pathways, as well as low‐level chronic inflammation, are believed to play a crucial role in premature skin ageing and skin cancer development [7](#ics12540-bib-0007){ref-type="ref"}, [8](#ics12540-bib-0008){ref-type="ref"}, [9](#ics12540-bib-0009){ref-type="ref"}. In this context, (non‐UVR‐absorbing) anti‐oxidant and anti‐inflammatory (AI/AO) ingredients integrated into sunscreen products have been shown to exert beneficial effects in skin photoprotection [10](#ics12540-bib-0010){ref-type="ref"}, [11](#ics12540-bib-0011){ref-type="ref"}, [12](#ics12540-bib-0012){ref-type="ref"}, [13](#ics12540-bib-0013){ref-type="ref"}.

Concerns have been raised recently, however, regarding the accuracy of the labelled SPF on sunscreen products which contain AI/AO ingredients such as bisabolol, allantoin or 18β‐Glycyrrhetinic acid [14](#ics12540-bib-0014){ref-type="ref"}, [15](#ics12540-bib-0015){ref-type="ref"}, [16](#ics12540-bib-0016){ref-type="ref"}. This is because visible erythema is the endpoint in human *in vivo* SPF determination (ISO24444:2010) and AI/AO ingredients could, at least theoretically, moderate this response after irradiation (thus resulting in sunscreens containing these substances bearing a higher SPF than that justified by the formulated sunscreen filters). Some have also raised concerns that sunscreen filters themselves, in particular salicylates, may have inherent AI/AO activity [17](#ics12540-bib-0017){ref-type="ref"}. Others have commented that, if these concerns were valid, consumers could wrongly assume adequate UVR protection [18](#ics12540-bib-0018){ref-type="ref"}.

Recently, other authors reported no significant difference in the measured SPF of sunscreen products with or without AI/AO ingredients [19](#ics12540-bib-0019){ref-type="ref"}, [20](#ics12540-bib-0020){ref-type="ref"}.

To further investigate the impact of AI/AO ingredients on measured SPF values, we performed two *in vivo* studies using the ISO24444(2010) protocol. SPF30 sunscreen products were tested containing a variety of AI/AO ingredients (Tocopheryl Acetate, Glycyrrhetinic Acid, Panthenol or Glycyrrhiza Inflata Root Extract). A control SPF30 sunscreen (containing no AI/AO ingredients) was also tested.

Material and methods {#ics12540-sec-0006}
====================

Sunscreen products {#ics12540-sec-0007}
------------------

Sunscreen formulations (oil‐in‐water \[O/W\] emulsion; expected SPF30) containing various AI/AO ingredients were prepared for the study. In Study I, formulations were used containing no AI/AO ingredients (vehicle control) or 1.0% Tocopheryl Acetate, 0.1% Glycyrrhetinic Acid, or 5.0% Panthenol, respectively. For study II, a formulation (O/W emulsion) containing no AI/AO ingredients (vehicle control) or the AI/AO ingredient Glycyrrhiza Inflata Root Extract (0.025%) were used. All formulations were the same except for the AI/AO ingredients and all contained the same concentration of the UVR filters homosalate, ethylhexyl salicylate, titanium dioxide, butyl methoxydibenzoylmethane and octocrylene.

In vivo determination of sun protection factor {#ics12540-sec-0008}
----------------------------------------------

The two SPF studies were performed according to the international standard protocol ISO24444:2010. While ISO24444:2010 requires a visual determination of skin erythema at 20 ± 4h after irradiation, an additional reading at 5h after irradiation was also implemented. The standard formulation P2 was included as a reference SPF product in both studies. The test institute was informed that the expected SPF value of the test products was in the range of SPF30--40.

The studies were executed at a certified contract research laboratory. In both studies, 10 subjects with Fitzpatrick skin types I, II and III were enrolled (Table [1](#ics12540-tbl-0001){ref-type="table"}) into and completed the SPF test (ITA° value range of 30--64 in Study I and 29--59 in Study II; the age range of subjects was 30--64 years in Study I and 29--59 in Study II).

###### 

Test panel demographics

                               Study I    Study II
  ---------------------------- ---------- ----------
  Test subjects                10         10
  Age: mean/range              30--64     18--69
  Gender: male/female          4/6        2/8
  Skin phototype: I, II, III   2, 4, 4,   1, 3, 6
  ITA° range, min ‐ max        30--64     29--59
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Study execution, data analysis and reporting were performed in line with Good Clinical Practice principles and the requirements of the Declaration of Helsinki. Test subjects were informed about the study, its objectives, probable benefits, potential risks, rights and responsibilities. Informed Consent was obtained in writing from each subject.

Statistics {#ics12540-sec-0009}
----------

Statistical analysis was performed using SAS‐Institute®JMP.Pro 14 software^®^.

A paired (within‐subject) analysis was performed for each time point (5 h and 24 h). Normality was probed using a Shapiro and Wilk's *W*‐Test. Where a normal data distribution was found, data were analysed using a Student's *t*‐test (with a mean comparison to 0). Where a non‐normal data distribution was found, a Wilcoxon Signed Rank test was used instead.

Results and discussion {#ics12540-sec-0010}
======================

In Study I, a W/O emulsion sunscreen product was used as the vehicle control and the SPF of this formulation was determined as 31.5 ± 6.5 at 20 ± 4 h after irradiation (Table [2](#ics12540-tbl-0002){ref-type="table"}) with a 95% confidence interval (CI) of 26.8--36.2 (CoV 14.8%). The identical vehicle formulated with either 1.0% Tocopheryl Acetate, 0.1% Glycyrrhetinic acid or 5.0% Panthenol returned tested SPF values of 30.7 ± 6.0, 34.1 ± 4.3 or 33.1 ± 5.5, respectively (Table [2](#ics12540-tbl-0002){ref-type="table"}).

###### 

SPF determination 20 ± 4 h post‐irradiation

  Formulation                 *n*   Mean   SD    95% CI   CI (%)   
  --------------------------- ----- ------ ----- -------- -------- ------
  Vehicle (Study I)           10    31.5   6.5   26.9     36.1     14.8
  +1.0% tocopheryl acetate    10    30.7   6.0   26.4     35.0     14.1
  +0.1% glycyrrhetinic acid   10    34.1   4.3   31.0     37.2     9.1
  +5.0% panthenol             10    33.1   5.5   29.2     37.0     11.9
  Standard P2                 10    15.1   2.4   13.3     16.9     11.5
  Vehicle (Study II)          10    32.4   5.0   28.8     36.0     11.0
  +0.025 licorice             10    30.1   4.6   26.8     33.4     10.9
  Standard P2                 10    14.8   2.6   12.9     16.7     12.5

*n*, number of subjects with visible erythema.
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In Study II, the W/O emulsion sunscreen used as the vehicle control returned a tested SPF of 32.4 ± 5.0 with a 95% CI of 28.8--36 (CoV 11.0%). The identical vehicle formulated with 0.025% Glycyrrhiza Inflata Root Extract returned a tested SPF value of 30.1 ± 4.1.

When the SPF was determined at 5 h after irradiation, most subjects did not show any measurable erythema reaction. While this led to an increase in the 95% CI, however, no influence of the AI/AO ingredients was evident.

In both Study I and Study II, variation of SPF values at 20 ± 4 h after irradiation was within the accepted range for SPF determination (CoV ≤ 17%) and the standard P2 returned the expected values (in Study I, the SPF of P2 was 15.1 and the CoV was 11.5%; in Study II the SPF was 14.8 and the CoV was 12.5 (Table [3](#ics12540-tbl-0003){ref-type="table"})). The W Test revealed a non‐normal distribution of data for Vehicle + 1% tocopheryl acetate and Vehicle + 5% panthenol and, therefore, a Wilcoxon Signed Rank test was used (Table [4](#ics12540-tbl-0004){ref-type="table"}). The *W* Test revealed a normal distribution of data for Vehicle + 0.1% glycyrrhetinic acid and Vehicle + 0.025% licorice and, therefore, a Student's *T*‐test was used (Table [4](#ics12540-tbl-0004){ref-type="table"}). For all products, the addition of AI/AO ingredients had no influence on determined SPF values.

###### 

SPF determination 5 h post‐irradiation

  Formulation                 n    Mean   SD    95% CI   CI (%)   
  --------------------------- ---- ------ ----- -------- -------- -------
  Vehicle (Study I)           4    39.5   9.5   24.4     54.6     38.4
  +1.0% tocopheryl acetate    4    38.1   8.2   25.1     51.1     34.0
  +0.1% glycyrrhetinic acid   4    38.2   6.7   27.5     48.9     27.8
  +5.0% panthenol             2    28.8   4.6   −12.5    70.1     143.6
  Standard P2                 6    16.4   3.7   12.8     16.9     23.6
  Vehicle (Study II)          7    29.5   4.6   25.2     33.8     14.5
  +0.025 licorice             7    29.8   3.5   26.6     33.0     10.8
  Standard P2                 10   15.3   3.5   12.8     17.9     16.4

*n*, number of subjects with visible erythema
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###### 

Paired analysis for 24 h

+---------------------------+------------------+--------------------+----------------+------------+-------------+-----+------------+
|                           | Shapiro--Wilk\'s | Difference Average | Difference SEM | Student\'s | Wilcoxon\'s | *n* | Conclusion |
|                           |                  |                    |                |            |             |     |            |
|                           | *P*‐value        |                    |                | *P*‐value  | *P*‐value   |     |            |
+===========================+==================+====================+================+============+=============+=====+============+
| Vehicle (Study I)         |                  |                    |                |            |             |     |            |
+---------------------------+------------------+--------------------+----------------+------------+-------------+-----+------------+
| +1.0% tocopheryl acetate  | 0.0027           | −0.7400            | 1.5447         | 0.6433     | 0.7500      | 10  | NS         |
+---------------------------+------------------+--------------------+----------------+------------+-------------+-----+------------+
| +0.1% glycyrrhetinic acid | 0.1877           | 2.6300             | 1.2886         | 0.0716     | 0.1094      | 10  | NS         |
+---------------------------+------------------+--------------------+----------------+------------+-------------+-----+------------+
| +5.0% panthenol           | 0.0223           | 1.6600             | 1.7788         | 0.3751     | 0.5781      | 10  | NS         |
+---------------------------+------------------+--------------------+----------------+------------+-------------+-----+------------+
| Vehicle (StudyII)         |                  |                    |                |            |             |     |            |
+---------------------------+------------------+--------------------+----------------+------------+-------------+-----+------------+
| +0.025 licorice           | 0.8765           | −2.3500            | 1.9952         | 0.2691     | 0.2031      | 10  | NS         |
+---------------------------+------------------+--------------------+----------------+------------+-------------+-----+------------+
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These results are in line with those of Werner *et al*. [20](#ics12540-bib-0020){ref-type="ref"}, who studied the influence of bisabolol and D‐panthenol (each up to 1.0%) on determined *in vivo* SPF in two different sunscreen formulations where, once again, no significant influence of these AI/AO ingredients on SPF values was measured in this study. The authors also applied the same formulations as an Après Sun treatment, where test subjects' skin was first irradiated and then treated immediately and again at 6, 12 and 24 h after irradiation. Once again, there was no influence of the formulations containing these AI/AO ingredients on UVR‐induced erythema when compared to the base formula without the inclusion of AI/AO technology.

This latter experimental approach to assess potential moderation of erythemal response because of anti‐inflammatory activity independent of UVR‐attenuation (that is, the application of topical formulations after irradiation), was first used by Staton and Feng in the study of the putative anti‐inflammatory efficacy of an SPF100 sunscreen formulation [21](#ics12540-bib-0021){ref-type="ref"}. Although this formulation did not contain recognized AI/AO ingredients, Sayre *et al.* [17](#ics12540-bib-0017){ref-type="ref"} had previously expressed concerns that UVR filters (especially salicylates) may possess AI/AO activity and may, therefore, moderate the generation of erythema in irradiated skin (especially when formulated at high concentrations up to 39%). In light of vigorous ensuing debate [22](#ics12540-bib-0022){ref-type="ref"}, [23](#ics12540-bib-0023){ref-type="ref"}, Staton and Feng [19](#ics12540-bib-0019){ref-type="ref"} were the first to test Sayre's hypothesis. In their study, they found no evidence for AI/AO activity because of the inclusion of high concentrations of certain UVR filters in a SPF100 product. Moreover, the authors added 1% hydrocortisone to the standard formulation P2 (nominal SPF16). Even the addition of this potent anti‐inflammatory corticosteroid did not significantly change erythemal response. While a small change in measured a\* value was recorded instrumentally (0.48--1.1 units), this change was not visible to the naked eye and did not influence SPF determination.

The concerns expressed by Couteau *et al*. [15](#ics12540-bib-0015){ref-type="ref"} that AI/AO ingredients might delay erythema and, thus, mislead consumers into protracted sun exposure was addressed in our studies by the inclusion of an additional erythema reading at 5 h post‐irradiation. Paired statistical analysis showed, once again, that there was no detectable influence of AI/AO ingredients on measured erythema (Table [5](#ics12540-tbl-0005){ref-type="table"}). The only difference to the standard measurement according to the ISO24444:2010 protocol (reading of erythema at 20 ± 4 h post‐irradiation) was an increase in confidence interval, because of the lack of erythema on test sites in many subjects at 5 h after irradiation. This absence of erythema at 5 h reflects the expected variability of erythema induction in the general population. Notwithstanding this observation, no effect for the addition of AI/AO could be detected.

###### 

Paired analysis for 5 h

+---------------------------+------------------+--------------------+----------------+------------+-------------+-----+------------+
|                           | Shapiro--Wilk\'s | Difference Average | Difference SEM | Student\'s | Wilcoxon\'s | *n* | Conclusion |
|                           |                  |                    |                |            |             |     |            |
|                           | *P*‐value        |                    |                | *P*‐value  | *P*‐value   |     |            |
+===========================+==================+====================+================+============+=============+=====+============+
| Vehicle (Study I)         |                  |                    |                |            |             |     |            |
+---------------------------+------------------+--------------------+----------------+------------+-------------+-----+------------+
| +1.0% tocopheryl acetate  | 0.4666           | 2.5000             | 4.5347         | 0.6368     | 1.0000      | 3   | NS         |
+---------------------------+------------------+--------------------+----------------+------------+-------------+-----+------------+
| +0.1% glycyrrhetinic acid | 0.7262           | −0.1000            | 2.8000         | 0.9748     | 1.0000      | 3   | NS         |
+---------------------------+------------------+--------------------+----------------+------------+-------------+-----+------------+
| +5.0% panthenol           | ‐                | ‐                  | ‐              | ‐          | ‐           | 1   | ‐          |
+---------------------------+------------------+--------------------+----------------+------------+-------------+-----+------------+
| Vehicle (Study II)        |                  |                    |                |            |             |     |            |
+---------------------------+------------------+--------------------+----------------+------------+-------------+-----+------------+
| +0.025 licorice           | 0.1603           | 1.5500             | 2.3717         | 0.5423     | 0.7500      | 6   | NS         |
+---------------------------+------------------+--------------------+----------------+------------+-------------+-----+------------+

Shapiro‐Wilk's *P*‐value (null hypothesis: the distribution is Normal) -- Normal if *P*‐value \>0.0500.

Difference average -- Product SPF minus Vehicle SPF per volunteer.

Difference SEM -- Difference Standard Error of Mean.

Student's *P*‐value (null hypothesis: the mean = 0) -- No significant difference if *P*‐value \>0.050.

Wilcoxon's *P*‐value (null hypothesis: number of positive differences = number of negative differences) -- Normal if *P*‐value \> 0.050.

*n* -- Number of available differences (SPF both evaluated for product and vehicle).

Conclusion (NS = No Significant, based on Student if Normal and Wilcoxon if not) -- Note: in case of no Normal distribution if the conclusions of Wilcoxon and Student match, the Student's *P*‐value can be used.
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AI/AO ingredients are used in many sunscreen products and our data (on file) demonstrate that they are welcomed by consumers. The main function of these ingredients is to provide additional technical benefit (for example, moderation of chronic skin damage because of low‐level pro‐oxidative and pro‐inflammatory stress, demonstrated by various authors for various ingredients; 7, 11, 12, 13).

AI/AO mechanisms are considered to help reduce the risk of non‐melanoma skin cancer and, therefore, inclusion of ingredients with this mode of efficacy in sun care products may be beneficial in protection against chronic skin damage because of solar UVR exposure [8](#ics12540-bib-0008){ref-type="ref"}, [10](#ics12540-bib-0010){ref-type="ref"}. In this present study, we have demonstrated that the tested AI/AO ingredients have no effect on measured *in vivo* SPF values. The main reason for under‐performance of sunscreen products in‐use is mis‐use by many consumers. For example, sunscreens are not always applied at the correct dosage, are often not applied homogeneously and re‐application is often not performed as recommended [24](#ics12540-bib-0024){ref-type="ref"}, [25](#ics12540-bib-0025){ref-type="ref"}.

The scope of this paper was solely to investigate the influence of AI/AO on the early development of erythema because the first 24 h after irradiation are crucial in the determination of sunscreen *in vivo* SPF. Because sunscreens are re‐applied frequently and erythema persists for more than 24 h, however, additional studies could be performed to explore the effects of AI/AO on skin change resulting from sub‐erythemal UVR exposure.

The studies were sponsored by Beiersdorf AG and executed by an independent contract research laboratory.
